I don't want to be negative seeing as I don't hold stock and all but I would be wary of Lind Partners.
You can research how they have savaged the SP of many biotechs by selling down on market when they get cheap entry.
I would be careful in terms of buying more, especially in the short-term (unless IVX release good news on any or all of the 3 Phase II's), seeing as this deal is a $17m equity draw down. Not sure why they needed so much? If they have good news, then they can get rid of this deal by raising equity as many others have done in the past.
I know I am going to catch heat but have a look at Consegna, now Rhinomed (RNO) and see what Lind Partners did to their SP.
I assume they didn't have much choice and needed the money, so took this route as they couldn't keep asking shareholders for handouts.
IVX Price at posting:
5.9¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)